Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 3/20 | 0.57 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CTRB1 | P17538 | 4/20 | 0.44 |
| ▸ | PPARG | P37231 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | CTSS | P25774 | 1/20 | 0.43 |
| ▸ | CTSK | P43235 | 1/20 | 0.43 |
| ▸ | CPA1 | P15085 | 1/20 | 0.42 |
| ▸ | CPA3 | P15088 | 1/20 | 0.42 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL684802 | 0.88 | POLB (0.51) | MTNR1AMTNR1BCYP1A2PPARGMAPT | |
| SCHEMBL1709763 | 0.84 | MTNR1A (0.64) | MTNR1AMTNR1BCYP1A2CTRB1MAPT | |
| SCHEMBL2327792 | 0.80 | MTNR1A (0.59) | MTNR1AMTNR1BCYP1A2CTRB1MAPT | |
| SCHEMBL2327788 | 0.80 | MTNR1A (0.59) | MTNR1AMTNR1BCYP1A2CTRB1MAPT | |
| SCHEMBL19483359 | 0.79 | CYP1A2 (0.55) | CYP1A2MAPTCPA1CPA3FOLH1 | |
| SCHEMBL1709341 | 0.79 | CYP1A2 (0.60) | CYP1A2PPARGMAPTCPA1CPA3 | |
| SCHEMBL19483390 | 0.79 | CYP1A2 (0.55) | CYP1A2MAPTCPA1CPA3FOLH1 | |
| SCHEMBL13594114 | 0.76 | MTNR1A (0.66) | MTNR1AMTNR1BCTRB1LMNAMAPT | |
| SCHEMBL1627622 | 0.75 | CTSS (0.58) | CTRB1LMNACTSSCTSK | |
| SCHEMBL8825845 | 0.75 | POLB (0.50) | MTNR1AMTNR1BCYP1A2PPARGMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180092883-A1 | PHOSPHATASE INHIBITORS FOR TREATING OCULAR DISEASES | EyePoint Pharmaceuticals, Inc. | 2018-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180092883-A1 | PHOSPHATASE INHIBITORS FOR TREATING OCULAR DISEASES | PPM1G, PPM1F, PPM1A | MTNR1A 2994/4885MTNR1B 2378/4885CYP1A2 4820/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.